Skip to main content
ArticleCOVID-19

ECMO support in COVID-19 patients with refractory ARDS

COVID-19 patients treated with extracorporeal membrane oxygenation (ECMO) appear to have a much lower mortality rate than initial early reports suggested.

ECMO has been utilized in COVID-19 patients with acute respiratory distress syndrome (ARDS) and hypoxemia that fails to respond to standard treatment. But early case series suggested a high mortality rate – topping 90%.

The in-hospital mortality rate was 45.9%, far lower than initial early reports and refuting previous reports of futility for ECMO in COVID-19 patients with ARDS.

Source: Reuters

Leave a Reply

error: